Who is this protocol a good fit for?

Anyone trying to understand what Ozempic or Wegovy actually is and what the evidence shows. Anyone comparing FDA-approved GLP-1 drugs to unregulated “research peptides”. Patients or caregivers preparing questions for a prescriber. Readers who want the approved-use boundary made explicit

What are the cautions for this protocol?

Educational only, not medical advice; any decision to start, stop, or dose semaglutide belongs with a licensed prescriber.. Compounded or gray-market “semaglutide” sold outside a licensed pharmacy has documented purity and dosing-error problems per FDA warnings.. Boxed warning: thyroid C-cell tumors were seen in rodent studies; discuss personal risk factors with a prescriber.

← Home / Peptides / YourProtocol / Semaglutide (Ozempic, Wegovy): Evidence and Safety

Peptides Peptides

Semaglutide (Ozempic, Wegovy): Evidence and Safety

Semaglutide is a GLP-1 receptor agonist that slows stomach emptying and reduces appetite. It is FDA-approved, as Ozempic for type 2 diabetes and Wegovy for chronic weight management, on the strength of large randomized trials, the strongest human evidence base of any peptide covered on this page. It is prescription-only; the real risk in practice is compounded, gray-market “semaglutide” sold outside a licensed pharmacy, which has documented purity and dosing-error problems.

💊

YourProtocol

YourProtocol Research

In-house · Synthesized from the cited primary sources

Daily time

5 min

Difficulty

Beginner

Sources

What the evidence says

What it is

Understand the mechanism

A GLP-1 receptor agonist: it mimics a gut hormone that slows stomach emptying, raises insulin release when blood sugar is high, and acts on brain appetite centers to reduce hunger.

This is a hormone-mimicking mechanism, not a stimulant-style appetite suppressant.

Wilding et al., NEJM 2021 (STEP trial program)

For this step

No product needed

Evidence tier: A

See what the trials actually showed

FDA approval rests on large randomized controlled trials: the STEP program for weight management and the SUSTAIN program for type 2 diabetes, both multi-thousand-patient RCTs published in the New England Journal of Medicine and replicated across trials.

This is the strongest human evidence base of any peptide on this page.

Wilding et al., “Once-Weekly Semaglutide in Adults with Overweight or Obesity,” NEJM 2021

For this step

No product needed

Legal status

Know what is and is not approved

FDA-approved: Ozempic for type 2 diabetes, Wegovy for chronic weight management. Prescription-only, dispensed through a licensed pharmacy.

The approval is indication-specific and prescription-gated, not an over-the-counter or general-use approval.

FDA approval record

For this step

No product needed

Safety

Know where the real risk sits

Documented side effects include nausea, GI upset, rare pancreatitis, and gallbladder issues, plus a boxed warning about thyroid C-cell tumors seen in rodent studies. The larger real-world risk is compounded or gray-market “semaglutide” sold outside the licensed pharmacy system, which the FDA has warned carries purity and dosing-error problems.

Sourcing, not the approved molecule itself, is where the practical danger concentrates.

FDA safety communications on compounded GLP-1 products

For this step

No product needed

What it is

Semaglutide mimics glucagon-like peptide-1 (GLP-1), a gut hormone that slows stomach emptying, increases insulin release when blood sugar is high, and acts on brain appetite centers to reduce hunger. This page is informational: it reports what semaglutide is, what its FDA approval actually covers, and why sourcing matters. It is not instructions for use; any decision to start, stop, or dose a prescription medication belongs with a licensed prescriber.

Why it works▼

Semaglutide's evidence base is the strongest of any peptide covered here. The STEP trial program (Wilding et al., New England Journal of Medicine, 2021) established weight-management efficacy in large randomized controlled trials, and the SUSTAIN trial program established its type 2 diabetes indication; both are multi-thousand-patient RCTs published in a top-tier journal and replicated across trials. Real, well-characterized side effects include nausea, GI upset, rare pancreatitis, and gallbladder issues, plus a boxed warning about thyroid C-cell tumors seen in rodent studies. The risk that gets underplayed is not the approved drug itself but compounded or gray-market “semaglutide” sold outside the licensed pharmacy supply chain, which the FDA has warned carries real purity and dosing-error problems.

The evidence

Sources 1

Primary sources behind this page, cited straight to the source: peer-reviewed papers and reporting. Select any to view it here.

Wilding et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), NEJM 2021

Paper

Source viewer

Loading the first source…

Is this for you?

Good fit if

Anyone trying to understand what Ozempic or Wegovy actually is and what the evidence shows
Anyone comparing FDA-approved GLP-1 drugs to unregulated “research peptides”
Patients or caregivers preparing questions for a prescriber
Readers who want the approved-use boundary made explicit

Cautions

Educational only, not medical advice; any decision to start, stop, or dose semaglutide belongs with a licensed prescriber.
Compounded or gray-market “semaglutide” sold outside a licensed pharmacy has documented purity and dosing-error problems per FDA warnings.
Boxed warning: thyroid C-cell tumors were seen in rodent studies; discuss personal risk factors with a prescriber.

Common questions

Is semaglutide the same as Ozempic or Wegovy?▾

Yes. Semaglutide is the active ingredient; Ozempic and Wegovy are brand names for the same molecule, FDA-approved for type 2 diabetes and chronic weight management respectively.

What is the actual evidence behind semaglutide?▾

Large randomized controlled trials: the STEP program for weight management and the SUSTAIN program for type 2 diabetes, both multi-thousand-patient trials published in the New England Journal of Medicine. It is the strongest human evidence base of any peptide covered on this page.

Is compounded semaglutide the same as the approved drug?▾

No. Compounded or gray-market versions sold outside the licensed pharmacy supply chain are not the FDA-approved product and have documented purity and dosing-error problems, per FDA warnings.

Get the next protocol first

New expert protocols and evidence updates, cited to the source. No spam; unsubscribe anytime.

Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.

Semaglutide (Ozempic, Wegovy): Evidence and Safety

Read the evidence

Read it